All In Biotech

Drug Trial Radar · NCT07326371

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

A Single-Center, Prospective Study Evaluating the Efficacy and Safety of Glofitamab Combined With CAR-T Therapy in Patients With High-Risk Relapsed/Refractory Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Jul 2027

Study completion Mar 2029

Sponsor

Lead sponsor
Ruijin HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma

Interventions

  • GlofitamabDrug

    Glofitamab IV infusion will be administered as per the schedule specified in the respective arm.

  • ObinutuzumabDrug

    Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

  • Axicabtagene CiloleucelDrug

    Axicabtagene Ciloleucel IV infusion will be administered as per the schedule specified in the respective arm.

  • Relmacabtagene autoleucel (relma-cel)Drug

    Relmacabtagene autoleucel IV infusion will be administered as per the schedule specified in the respective arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CRR)Time frame: Baseline up to the end of treatment (EOT) (approximately 4 months)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.